CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Trading 03-04 12:29:33 EST

7.11

+0.20

+2.89%

High7.15	Low6.92	Vol440.85K
Open6.97	D1 Closing6.91	Amplitude3.26%
Mkt Cap560.18M	Tradable Cap523.96M	Total Shares78.79M
T/O3.11M	T/O Rate0.60%	Tradable Shares73.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":7.1099,"timestamp":1772645369317,"preClose":6.91,"halted":0,"volume":440847,"delay":0,"changeRate":0.028929088277858107,"floatShares":73694900,"shares":78789045,"eps":2.0624602,"marketStatus":"Trading","change":0.1999,"latestTime":"03-04 12:29:33 EST","open":6.97,"high":7.145,"low":6.92,"amount":3112455.4693452003,"amplitude":0.032562,"askPrice":7.11,"askSize":379,"bidPrice":7.1,"bidSize":720,"shortable":3,"etf":0,"ttmEps":2.0624602,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772658000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":6.91,"preHourTrading":{"tag":"盘前","latestPrice":7,"preClose":6.91,"latestTime":"09:29 EST","volume":2174,"amount":15263.3002902,"timestamp":1772634541066,"change":0.09,"changeRate":0.013025,"amplitude":0.007236},"postHourTrading":{"tag":"盘后","latestPrice":6.9501,"preClose":6.91,"latestTime":"19:50 EST","volume":36484,"amount":252198.241,"timestamp":1772585429947,"change":0.0401,"changeRate":0.005803,"amplitude":0.005803},"volumeRatio":0.808811,"impliedVol":0.8463,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/CRMD/tweets","defaultTab":"tweets","newsList":[{"id":"2616330677","title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330677","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330677?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:30","pubTimestamp":1772458200,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., March  02, 2026  (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247400/0/en/CorMedix-Inc-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provide-a-Corporate-Update-on-March-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2610495065","title":"CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2610495065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610495065?lang=en_us&edition=fundamental","pubTime":"2026-02-12 01:57","pubTimestamp":1770832635,"startTime":"0","endTime":"0","summary":"CorMedix's  near-term growth prospects will be shaped by upcoming clinical data, particularly around the potential use of Rezzayo to prevent invasive fungal infections in high-risk transplant and cancer patients, RBC Capital Markets said Tuesday in a report.At the company's research and development event, clinicians said Rezzayo's clean safety profile, few interactions with other medications, high initial drug levels, and once-weekly IV dosing could make it well-suited for prophylaxis in immunocompromised patients, the report said. Management estimates the prophylaxis market at $2 billion, while RBC models about $150 million in potential revenue based on a 10% share.Physicians also highlighted the drug's advantages in treating invasive fungal infections, noting that Rezzayo is currently used mostly in later-line settings, the report said. Broader adoption in treatment will likely require additional data and insurer coverage decisions, RBC said.For DefenCath, management and panelists po","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2610693267","title":"CorMedix Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693267","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610693267?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:19","pubTimestamp":1770812340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2026 07:19 ET (12:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2608898579","title":"CorMedix Authorizes Up to $75 Million Stock Buyback; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2608898579","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608898579?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:10","pubTimestamp":1770045022,"startTime":"0","endTime":"0","summary":"CorMedix  said its board approved a stock repurchase program of up to $75 million.The buyback, which may begin as early as Q1, is authorized through Dec. 31, 2027, the company said Monday in a statement.CorMedix shares rose 6.6% in Monday trading.Price: 8.28, Change: +0.52, Percent Change: +6.64","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2608864789","title":"CorMedix board authorizes share repurchase program of up to $75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864789","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608864789?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:35","pubTimestamp":1770039315,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) Therapeutics announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-board-authorizes-share-repurchase-program-of-up-to-75m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-board-authorizes-share-repurchase-program-of-up-to-75m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2608646508","title":"CorMedix Therapeutics Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2608646508","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608646508?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:30","pubTimestamp":1770039003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1ZBTVS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2607080227","title":"CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2607080227","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607080227?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:31","pubTimestamp":1769693472,"startTime":"0","endTime":"0","summary":"CorMedix Inc. will host an in-person and virtual analyst day in New York on February 10, 2026. The event will include presentations and panels featuring key opinion leaders and the company’s senior management, focusing on updates across CorMedix’s portfolio and pipeline, as well as discussions of key growth drivers and upcoming milestones. The session will highlight the commercial opportunity for the REZZAYO and DefenCath programs, both currently in Phase III clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL43Fv8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","CRMD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","BK4007","IE00BKPKM429.USD","LU2210150020.SGD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2606257620","title":"Is CorMedix (CRMD) A Potential Opportunity After Recent Share Price Volatility?","url":"https://stock-news.laohu8.com/highlight/detail?id=2606257620","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606257620?lang=en_us&edition=fundamental","pubTime":"2026-01-25 19:27","pubTimestamp":1769340434,"startTime":"0","endTime":"0","summary":"If you are wondering whether CorMedix at around US$7.27 is priced as a bargain or a trap, you are not alone. That is exactly what this valuation focused rundown aims to unpack.\nThe stock has been volatile recently, with a 7.2% gain over the last 7 days, a 42.0% decline over 30 days, and year to date and 1 year returns of 40.2% and 41.5% declines. The 3 year return sits at 68.7% and the 5 year return at a 16.9% decline.\nRecent trading moves have put CorMedix back on the radar for investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/is-cormedix-crmd-a-potential-opportunity-after-recent-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/is-cormedix-crmd-a-potential-opportunity-after-recent-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRMD","DCF","BK4007"],"gpt_icon":0},{"id":"2605758472","title":"CorMedix Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605758472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605758472?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:08","pubTimestamp":1769170080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 07:08 ET (12:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2605712194","title":"CorMedix Inc : H.c. Wainwright Cuts Target Price to $13 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2605712194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605712194?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:13","pubTimestamp":1769166799,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO0PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2605474397","title":"CorMedix price target lowered to $13 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2605474397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605474397?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:10","pubTimestamp":1769166642,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on CorMedix (CRMD) to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2605476314","title":"CorMedix Inc. Director Janet Dillione Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605476314","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605476314?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:30","pubTimestamp":1769135442,"startTime":"0","endTime":"0","summary":"Janet Dillione, Director of CorMedix Inc., reported a disposal of common shares of CorMedix Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDLlpqXv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CorMedix Inc. Director Janet Dillione Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2605796105","title":"CorMedix Inc : RBC Cuts Target Price to $13 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2605796105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605796105?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:04","pubTimestamp":1768993491,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2603953622","title":"CorMedix Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Michael David Seckler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603953622","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603953622?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:25","pubTimestamp":1768530343,"startTime":"0","endTime":"0","summary":"CorMedix Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Michael David Seckler, who serves as Chief Commercial Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL6wT7pJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CorMedix Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Michael David Seckler","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2603633968","title":"CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603633968","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603633968?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:16","pubTimestamp":1768302962,"startTime":"0","endTime":"0","summary":"Leadership moves and fresh guidance at CorMedix\nCorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$320 million, alongside appointing Mike Seckler as EVP & Chief Commercial Officer.\nSee our latest analysis for CorMedix.\nThe leadership changes and fresh 2026 revenue guidance arrive after a sharp pullback in CorMedix’s share price. The 7 day share price return shows a decline of 36.50% and the year to date...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRMD"],"gpt_icon":0},{"id":"2603085579","title":"Analysts Conflicted on These Healthcare Names: Cormedix (CRMD), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603085579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603085579?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:20","pubTimestamp":1768274412,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), BioMarin Pharma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","IE0002270589.USD","LU2065169927.USD","BK4581","BK4566","BK4137","LU2065171311.SGD","XBI","LU0029874061.USD","BMRN","LU0128526141.USD","BK4007","ACAD","BK4585","CRMD","LU2065170008.USD","LU2065171402.SGD","IE00B19Z3581.USD","HCSG","BK4139","IE00B7SZLL34.SGD","BK4588","IE00B19Z3B42.SGD","LABU"],"gpt_icon":0},{"id":"1134045879","title":"Stock Track | CorMedix Inc. Plummets 5.24% Intraday After Leerink Partners Slashes Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1134045879","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134045879?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228577,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) saw its stock plummet by 5.24% during intraday trading on Monday, following a significant target price cut by Leerink Partners.The investment firm reduced its target price for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2602512187","title":"CorMedix Inc : Leerink Partners Cuts Target Price to $15 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512187?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:28","pubTimestamp":1768220885,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"1143784563","title":"Stock Track | CorMedix Inc. Soars 5.46% Intraday as CEO Prepares for J.P. Morgan Healthcare Conference Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1143784563","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143784563?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:32","pubTimestamp":1767969140,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) saw its stock price surge by 5.46% during Friday's intraday session, reflecting strong investor optimism.The rally appears to be driven by the announcement that CorMedix's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2602376096","title":"CorMedix CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376096?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965451,"startTime":"0","endTime":"0","summary":"CorMedix Inc. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30pm PST. Chairman and CEO Joseph Todisco is scheduled to deliver the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3l57TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","CRMD","BK4588","SG9999014013.SGD","SG9999014039.USD","BK4007","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.1095},{"period":"3month","weight":-0.3304},{"period":"6month","weight":-0.4602},{"period":"1year","weight":-0.2795},{"period":"ytd","weight":-0.4058}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.133293},{"month":2,"riseRate":0.5,"avgChangeRate":0.066552},{"month":3,"riseRate":0.5,"avgChangeRate":0.042394},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.013888},{"month":5,"riseRate":0.2,"avgChangeRate":-0.123071},{"month":6,"riseRate":0.5625,"avgChangeRate":0.053114},{"month":7,"riseRate":0.4375,"avgChangeRate":0.055385},{"month":8,"riseRate":0.5625,"avgChangeRate":0.025363},{"month":9,"riseRate":0.375,"avgChangeRate":0.027376},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction